AI/ML investment strong as UK biotech weathers economic strain
With Q3 2025 venture capital figures representing “a fragile moment” for the UK biotech sector, BIA says sustained government action is needed to secure its global competitive edge.
List view / Grid view
With Q3 2025 venture capital figures representing “a fragile moment” for the UK biotech sector, BIA says sustained government action is needed to secure its global competitive edge.
Gains access to OTX-201, a preclinical CAR T therapy being developed to treat autoimmune diseases.
Once completed, the Berlin site will also be the new home for one of the company’s Bayer Co. Lab start-up incubators.
Deal with Kaerus Bioscience for KER-0193 could be worth $450m to the UK-based biotech.
Significant investment in advanced technologies Is expected to support global adoption of mass spectrometry in the next five years.
First-of-its-kind case continues EMA and MHRA harmonisation, streamlining the global biosimilar approval pathway.
The European Commission hopes its planned legislation will enable biotechnology companies to bring products from laboratory to market more quickly.